Drugs / RGT001-075
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06867718 | Jan → Nov 2025 | obesity disorder | Regor Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 2 | NCT06277934 | Mar → Aug 2024 | obesity disorder | Regor Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 2 | NCT05297045 | Mar 2022 → May 2023 | type 2 diabetes mellitus | Regor Pharmaceuticals Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RGT001-075 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06277934 ↗ |
| Action | Activate | “GLP1 receptor agonist” NCT05297045 ↗ |
| Modality | Small molecule | “RGT001-075 is a small molecule GLP-1 agonist” NCT06867718 ↗ |
| Route | Oral | “daily (QD) oral RGT001-075” NCT05297045 ↗ |